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Abstract
Human growth has an estimated heritability of about 80%–90%. Nevertheless, the underlying cause of shortness of stature
remains unknown in the majority of individuals. Genome-wide association studies (GWAS) showed that both common
single nucleotide polymorphisms and copy number variants (CNVs) contribute to height variation under a polygenic model,
although explaining only a small fraction of overall genetic variability in the general population. Under the hypothesis that
severe forms of growth retardation might also be caused by major gene effects, we searched for rare CNVs in 200 families,
92 sporadic and 108 familial, with idiopathic short stature compared to 820 control individuals. Although similar in number,
patients had overall significantly larger CNVs (p-value,161027). In a gene-based analysis of all non-polymorphic
CNVs.50 kb for gene function, tissue expression, and murine knock-out phenotypes, we identified 10 duplications and 10
deletions ranging in size from 109 kb to 14 Mb, of which 7 were de novo (p,0.03) and 13 inherited from the likewise
affected parent but absent in controls. Patients with these likely disease causing 20 CNVs were smaller than the remaining
group (p,0.01). Eleven (55%) of these CNVs either overlapped with known microaberration syndromes associated with
short stature or contained GWAS loci for height. Haploinsufficiency (HI) score and further expression profiling suggested
dosage sensitivity of major growth-related genes at these loci. Overall 10% of patients carried a disease-causing CNV
indicating that, like in neurodevelopmental disorders, rare CNVs are a frequent cause of severe growth retardation.
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Introduction
Human growth is a highly complex and multifactorial trait,
with an estimated heritability of about 80–90% [1]. Since 3%
of the general population present with a body height below -2
SD scores (SDS), shortness of stature is one of the common
medical concerns in childhood. Uncovering the genetic basis of
short stature is not only important for clinical diagnosis,
prognosis and genetic counseling of affected individuals and
their families, but is also a prerequisite for future development
of therapeutic approaches.
In clinical terms, short stature is divided into non-syndromic and
syndromic forms, the latter affecting additional distinctive organ
systems like brain and heart. In both forms growth retardation can
either be of intrauterine or postnatal onset. A disproportion between
the limbs and trunk is usually attributed to dysfunctional bone
maturation or differentiation. Elucidation of the genetic basis of skeletal
dysplasias has highlighted central defects in extracellular proteins,
metabolic pathways, signal transduction mechanisms, core proteins,
oncogenes and genes processing RNA and DNA as underlying
mechanisms of growth [2–4]. However, skeletal dysplasias are rare [5],
and the most common known causes of short stature are a
dysfunctional growth hormone pathway, deficiency of the transcription
factor SHOX and Ullrich-Turner syndrome in women [6–8]. After
excluding these known defects the underlying cause remains unknown
in approximately 80% of patients [8–10].
Many studies of copy number variants (CNVs) in patients with
neuropsychiatric conditions or multiple congenital anomalies showed
that de novo or inherited CNVs are pathogenic in up to 20% of patients
[11,12]. With an intermediate length of 1 kb to several Mb they
include both duplications and deletions and can affect single exons, one
or several genes as well as regulatory sequences. Unraveling pathogenic
CNVs by molecular karyotyping also provided new opportunities to
identify the genetic basis of several monogenic human diseases [13–16].
In this report we present the results of copy number detection in
a study group of 200 patients with idiopathic short stature. Based
on our hypothesis of rare variants involved in the frequent
phenotype of growth retardation, we provide evidence of
underlying CNVs in 10% of these patients in a gene based
approach. These CNVs encompass known microaberration
syndrome regions as well as de novo or inherited regions not yet
associated with short stature but containing GWAS loci for height.
Results/Discussion
We now recruited a group of 200 individuals and their families
with idiopathic short stature seen in the genetic clinic of the
Institute of Human Genetics at the University of Erlangen-
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Nuremberg to identify yet unknown genetic factors of growth
retardation. Height adjusted SD scores were calculated on basis of
the Prader Growth charts [17]. We included patients with a height
standard deviation score (SDS) of below 22 based on population
data or who are significantly below the expected target height for
their family. Common causes of short stature such as growth
hormone deficiency, Ullrich-Turner syndrome, and SHOX
deficiency were excluded where applicable. All patients underwent
detailed clinical and dysmorphological evaluation by one of the
authors (C.T.T.) and were classified as non-specific for any known
genetic aberration. Our study group included 131 patients with
isolated short stature (Table 1). 69 individuals presented with
additional features such as malformations or a dysmorphic facial
gestalt. The mean height SDS was 22.75. 52 individuals showed
severe growth retardation of prenatal onset. Patients with
significant body disproportions indicating skeletal dysplasias were
considered a distinct aetiological group and were not included in
this study [4,18]. Only patients with disproportionate short stature
but without radiographic signs suggestive of skeletal dysplasias
were retained. A borderline IQ in the range of learning disability
was observed in 3%. As these individuals received regular
education no specific developmental assessment was available. A
control cohort used to exclude common copy number polymor-
phisms consisted of 820 individuals originating from the same
Central European region with either exfoliation syndrome or
psoriatic arthritis [19], both late onset disorders not associated
with short stature. Copy number variants as a cause of these
disorders were foremost excluded and not reported in the
literature.
Molecular karyotyping of the 200 patient and the 820 control
samples was performed using Genome-Wide Human SNP 6.0 or
CytoScan HD arrays (Figure 1). All samples met in-house quality
criteria. Overall, we detected 6,338 copy number changes with an
average of 32 aberrations per affected individual (Figure 2). When
comparing the size range of all observed CNVs in patients (6,338
CNVs) and controls (40,935 CNVs) we determined a size
threshold at 99.2 kb (Figure 3A) and found a higher incidence of
CNVs with a length of above 100 kb in affected individuals
(p-value 1.18861027) (Figure 3B). To test for effects of common
variants we performed a genome wide CNV association analysis
calculating a permutation-based p-value across the CNVs of all
individuals. As expected regarding the small cohort size, genome
wide association at SNP level to the 20 loci where we identified
rare variants was excluded (Figure S1).
In an attempt to further investigate the variants under a
‘‘frequent disease - rare variant’’ – hypothesis to identify major
gene effects we excluded frequent copy number polymorphisms by
screening against 40,935 CNVs of the 820 control individuals
(Figure 1). As we suspected low penetrance alleles to be also
present in the control group, we only excluded CNVs with an
overlap in CNV size of 95% in more than 15 control samples
(approx. 2%). 1,211 aberrations .50 kb were retained. In a gene-
centric approach we also excluded aberrations which only affected
intronic or intergenic sequences. The remaining 733 CNVs were
reviewed for gene content and familial segregation with the growth
phenotype either by array analysis or by multiplex ligation-
dependent probe amplification (MLPA; Table S1). We retained all
CNVs that were either de novo in the sporadic cases or co-
segregated with the phenotype in the familial cases. In addition
both groups had to meet at least one of the following criteria: a)
CNVs with previously described human growth phenotypes of the
affected genes obtained from the OMIM database, b) Murine
knock-out phenotypes of the Mouse Genome Informatics database
(http://www.informatics.jax.org) including keywords like growth
retardation and decreased body size (Table S2), c) genes with a
possible role in height development and/or bone growth based on
their reported function on cell cycle regulation, organization of the
cytoskeleton, chromatin remodeling, cilia development and the
involvement in important developmental pathways (Table S3), d)
loci overlapping non-polymorphic, gene-containing aberrations of
the Decipher database (http://decipher.sanger.ac.uk) with short
stature as one of the described phenotypes.
Taken together all lines of evidence we identified a total of 20
likely pathogenic copy number changes, 10 deletions and 10
duplications, in 20 families (10% of the study group) (Table 2). It is
striking that in the RefSeq exons covered by all 20 CNVs we found
no overlapping control CNVs at all in 19 and just one control CNV
overlapping some exons in the 5p15.33 CNV (Table S3). The size of
these 20 CNVs ranged from 109 kb to 14 Mb. All 20 CNVs were
independently confirmed by MLPA (Figure S2A–S2T). 7 aberra-
tions (35%), 4 deletions and 3 duplications, were de novo (parental
relationships confirmed) with an average size of 2,594 kb and an
average of 30 genes. As we expected 661023 de novo CNVs per
haploid genome per generation in the healthy population [20], the
Table 1. Overview of the phenotypic characteristics of the
patient group.
Feature Patients (%)
Total 200
Male/Female 82 (41)/118 (59)
Mean standard deviation score (SDS) at birth 21.1
Mean standard deviation score (SDS) 22.75
Proportionate/disproportionate 170 (85)/30 (15)
Syndromic/isolated short stature 69 (34.5)/131 (65.5)
Primordial growth retardation yes/no 52 (26)/148 (74)
Intellectual status normal/mild learning disability 148 (74)/52 (26)
doi:10.1371/journal.pgen.1003365.t001
Author Summary
With a frequency of 3%, shortness of stature is a common
medical concern. Although family studies have clearly
shown that gene defects play a pivotal role in the
development of short stature, the underlying genetic
variants involved remain unknown in about 80% of cases.
In contrast to recent studies which aimed at the
identification of common genetic variants to explain minor
differences in the height variation in the general popula-
tion, we targeted rare genomic variants where we
expected a major gene effect on growth. By examining
200 patients clinically evaluated for short stature, we show
that rare structural chromosomal aberrations (CNVs) are
associated with shortness of stature in 10% of the cases.
The identified CNVs were either de novo or segregated
with short stature in the families and include genes that
are functionally involved in growth regulation in humans
or mice. We furthermore demonstrate an overlap of these
CNVs with known microdeletion syndromes. Interestingly,
3 CNVs contain positions of common variants and confirm
the localization of major growth-related genes. These
findings are particularly important for identification of
biological pathways leading to short stature, but also for
further therapeutic approaches.
Copy Number and Short Stature
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Figure 1. CNV discovery and characterization. Molecular karyotyping was performed for 200 patients with short stature after thorough clinical
evaluation and for 820 healthy control samples. Exclusion of common variants using the control samples and scoring CNVs above 50 kb resulted in
an approx. reduction of 80% of the CNVs identified in the patient samples. 60.5% of these CNVs affect reference sequence gene regions. Functional
characterization includes segregation analysis using parental arrays and/or MLPA as well as gene and CNV based evaluation.
doi:10.1371/journal.pgen.1003365.g001
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identified number of de novo CNVs.50 kb in our patients was
significantly higher than expected by chance further supporting
pathogenicity of these variants (p-value 0.03, Fisher’s exact test).
Unlike other entities with reduced reproductive fitness e.g.
severe intellectual disability with a high rate of de novo CNVs
[21,22], we anticipated a higher rate of inherited CNVs in short
stature as no reproductive disadvantage is known. This was
confirmed by the identification of 13 inherited CNVs with an
average CNV size of 1,727 kb and an average of 10 genes.
This group of 20 affected individuals with highly probable
pathogenic CNVs consisted of 9 male and 11 female individuals
(Table 3). Interestingly, the mean SD score for height was 23.34
and the SD score distribution of these 20 individuals was
significantly lower when compared to the total study group (p-
value 0.009; Wilcoxon test) (Figure 4). Thus, rare pathogenic
CNVs are more likely identified in patients with severe short
stature. No significant difference was observed in patients with
CNVs with prenatal vs. postnatal onset, proportionate vs.
Figure 2. Molecular karyotyping and MLPA confirmation of identified loci. (A) Example representation of the copy number analysis of
patient 1 using the Affymetrix Genotyping Console 3.0.2 software. The red bar shows the 2.2 Mb deletion region (CNSegments). (B) Graphical
presentation of the deletion region including 33 candidate genes (modified from UCSC genome browser). (C) MLPA confirmation with a probe in the
NFASC gene region. A relative quantity value (RQ) below 0.75 was considered as confirmation of a deletion, above 1.25 as confirmation of a
duplication. Detailed data for the remaining patients is presented in the supporting information.
doi:10.1371/journal.pgen.1003365.g002
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disproportionate growth retardation, and syndromic vs. non-
syndromic short stature (Table S4), but the number of affected
cases in each group was small with limited statistical power.
However, 40% of the 20 patients had a prenatal onset of short
stature compared to 26% of the entire study group indicating
central regulatory pathways of embryonic development to be
disturbed by genes located in these CNVs.
Eight patients had CNVs showing an overlap with 6 known
microdeletion/duplication syndromes associated with short stature
(Table 2). Two of these patients (patient 8 and 19) had large inherited
deletions covering the complete 1q21.1 microdeletion region which
is known for its phenotypic variability [23]. Short stature is present in
about 25–50% of the patients [24]. Further commonly observed
signs such as mild facial anomalies, microcephaly and developmental
delay were also observed in our patients. The inherited 307 kb
duplication of patient 12 included the distal end of the TAR
syndrome susceptibility locus on 1q21.1 but without the recently
reported RBM8A gene region [25]. A 1.6 Mb duplication overlap-
ping the rare 3q29 microdeletion/duplication syndrome was found
de novo in one patient with non syndromic idiopathic short stature
(patient 7). Features of the 3q29 duplication syndrome have not been
clearly determined, but failure to thrive has occasionally been
reported [26]. We also found a 1,363 kb de novo deletion partially
overlapping the classical and distal 22q11.22 microdeletion region of
DiGeorge/Velo-cardio-facial syndrome [27–29] and a 259 kb
inherited deletion within the distal part of 22q11.22 only (patient 4
and 9, respectively) [27]. Correspondingly, these two patients
presented with short stature and some mild facial features, but no
cardiac defects. Inherited duplications in patient 13 and 15 slightly
overlapped the microdeletion regions 2q33 and 1p36 [30,31]. Thus,
the clinical presentation of these patients confirmed the broad
variability of known microdeletion/duplication syndromes and
might highlight potential candidate genes for the short stature
phenotype in these entities.
Recent genome-wide association studies (GWAS) found com-
mon single nucleotide polymorphisms (SNPs) in at least 180 loci to
be significantly associated with height variation in the general
population. These associated loci accounted only for up to 10% of
the phenotypic variation within the normal range of the Gaussian
growth distribution [32]. We investigated if these loci might be
located within our identified rare CNVs. Using LocusZoom [33]
we compared position and gene content with the published
genome wide association dataset of the GIANT consortium based
on the CEU 1000genomes Nov 2010 imputation. To identify
significant loci, we considered a Bonferroni corrected level of
significance of 1.37761026 based on 36,316 SNPs from the
GIANT dataset located in the 20 identified CNVs. Loci at 3 of our
CNV regions reached this level of significance (variants with the
best p-values respectively r2 values are shown in Figure S3A–S3T
and Table S5). The loci with the best p-values were located in the
6.7 Mb deletion 2q36.1–36.3 (patient 2) (Figure 5), 4.5 Mb
duplication 2p23.3 (patient 5), and 14.2 Mb duplication 5q22.1-
q23.2 (patient 11). rs11125884 located in the promoter region of
EFR2B (patient 5) even reached a level of genome wide
significance based on SNP association (2.8610213). This number
of 3 CNVs with significant associated SNP loci out of the 20 likely
pathogenic CNVs was significantly higher than expected by
chance (p-value,161023). Our findings not only confirmed the
significance of the published results of the genome wide association
study but also suggest a possible functional link between common
variants in growth variation and rare variants involved in severe
growth retardation underlining a major gene effect in short
stature.
A deletion or duplication of one gene or a subset of genes
located in a CNV can lead to directly or indirectly impaired gene
expression [34,35]. To investigate whether this is the case for the
20 identified CNVs we performed expression profiling in 11
individuals where RNA from lymphocytes was available. Of the
Figure 3. Higher incidence of CNVs with a length of above 100 kb in affected individuals. (A) Presentation of the Odds Ratio (light blue)
and –log10(p-value) (dark blue) for determination of the size threshold of the number of CNVs in patients vs. controls. The Odds Ratio and the –
log10(p-value) confirms a CNV size cut-off at 99.2 kb (OR 1.26 and p-value 4.9861028). (B) Fraction of copy numbers segments in cases (grey) vs.
control (white) quintiles (* p,0.005). Quintile borders were Q1: 68.3 kb, Q2: 99.3 kb, Q3 149.6 kb, Q4 298.1 kb, and Q5: 72,571.3 kb. The y axis
presents the fraction of CNVs inside the corresponding quintile bin. Significance levels are calculated using Fisher’s exact test. The figure shows a shift
towards segments above 100 kb in patients (** p-value 1.18861027).
doi:10.1371/journal.pgen.1003365.g003
Copy Number and Short Stature
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188 genes contained in the CNVs 58 (31%) showed a significant
differential gene expression in the direction of the respective CNV
(Table S6). This number of differentially expressed genes we
observed would be expected by chance only with a probability of
less than 0.001 according to the binomial distribution, suggesting
that these genes are dosage sensitive and the identified aberrations
are leading to haploinsufficiency of these genes. To explore
whether these 58 differentially expressed genes cluster in networks
known to be involved in growth we performed pathway analyses
using Ingenuity Pathway Analysis (IPA). This analysis identified
networks involving cell death, cell cycle and DNA repair (Table
S7) further supporting the pathogenicity of these CNVs.
In conclusion, we propose rare CNVs as a relatively common
cause of short stature under a major gene effect model. These
include duplications as well as deletions of more than 100 kb in a
comparable frequency as observed in other entities e.g. intellectual
disability [12,36]. Our findings also provide strong evidence for a
‘‘rare variant – frequent disease’’ hypothesis for short stature.
Materials and Methods
Patient cohort
All individuals gave their consent to this study, which was
approved by the Ethical Review Board of the Friedrich-Alexander
University Erlangen-Nuremberg. Phenotypic data, medical histo-
ry, and family history of 200 affected individuals with short stature
and their family members were ascertained and compiled in a
database. In all cases photographic documentation, pediatric and
partially radiological evaluation was available. Height adjusted SD
scores were calculated on the basis of the Prader Growth charts. A
control cohort used to exclude common copy number polymor-
phisms consisted of 820 individuals originating from the same
Central European region with either exfoliation syndrome or
psoriatic arthritis. DNA and RNA of the affected individuals and
Figure 4. Height distribution of the study group. Height distribution (SDS) of all 200 patients (blue) compared to the 20 patients with identified
CNVs (green). The mean SD score for height was 23.34. Patients with identified CNVs showed a significant difference in the SDS distribution (p-value
0.03).
doi:10.1371/journal.pgen.1003365.g004
Table 3. Summary phenotype of patients with identified
CNVs.
Segregation
Feature total de novo inherited
Number of patients 20 7 13
Male/Female 9/11 4/3 5/8
Mean standard deviation score (SDS) 23.34 23.84 23.07
Proportionate/disproportionate 16/4 7/0 9/4
Syndromic/isolated 8/12 3/4 4/9
Intellectual status normal/mild learning
disability
11/9 3/4 8/5
Primordial growth retardation yes/no 8/12 2/5 6/7
Mean aberration size (kb) 2030 2594 1727
doi:10.1371/journal.pgen.1003365.t003
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DNA of their respective parents were obtained. DNA of cases and
controls was extracted from blood samples using the same method
and all necessary quality assessments during DNA sample and
array preparation were attributed. Principal component analysis of
the 200 affected and 820 control individuals demonstrated minor
ethnic heterogeneity within both cases and controls caused by a
residual amount of ethnic heterogeneity in both populations
(Figure S4). This was comparable in both and considered not
relevant for the identification of rare variants in contrast to the
classical test of association not applied in this study.
Molecular karyotyping
Molecular karyotyping was performed using Genome-Wide
Human SNP 6.0 and CytoScan HD arrays (Affymetrix, Santa
Clara, USA). We calculated the genome wide copy number using
the Genotyping Console 3.0.2 and the Chromosome Analysis
Suite v1.2.2 software (Affymetrix, Santa Clara, USA). To exclude
batch effects, all cases and controls were processed randomly. In-
house quality criteria of a contrast QC value .0.4 and a MAPD
value ,0.4 were met by all 200 samples. Instead of the Affymetrix
reference model file, our own reference file was created using 167
healthy control samples on the same platform with equal
conditions. Copy number variants with a minimum of 10 kb
and 5 affected markers (Genome-Wide Human SNP 6.0) or 20
affected markers (CytoScan HD array) were calculated. As CNV
calling for the Y chromosome was not reliable, CNVs on the Y
chromosome were excluded from further investigation.
At first a screening of all identified CNVs above 50 kb against
an independent control cohort of 820 healthy control individuals
excluded common copy number polymorphisms. 50 kb was the
observed minimum resolution of the arrays where independent
validation leads to reliable results. Accordingly, aberrations which
showed a size overlap of more than 95% in more than 15 control
samples were automatically excluded from further investigation.
CNVs with less than 95% overlap in control samples but where all
included genes are covered in CNVs of at least 15 control samples
were also removed. As we aimed for rare variants all remaining
CNVs were compared with CNVs annotated in the Database of
Genomic Variants to exclude common variants which might not
be covered by CNVs of our 820 control individuals. No additional
CNVs were excluded in this step.
CNV validation
Multiplex ligation-dependent probe amplifications (MLPAs)
were carried out using self-made MLPA kits with the SALSA
MLPA Reagents kit and the P200 SALSA MLPA Reference kit
according to the manufacturer’s instructions (MRC Holland,
Amsterdam, Netherlands). The reference kit includes control
fragments and reference probes from 172 to 250 nucleotides.
Corresponding to the affected copy number regions, MLPA
probes were designed as described in the general guidelines of
synthetic probe design by MRC Holland with the hg18 version of
the human reference sequence (NCBI36, March 2006). For all
oligonucleotides the RAW program was used to ensure a melting
temperature of $70uC and a GC content of about 40–60%. The
absence of annotated SNPs and a unique hybridization site was
verified with the BLAT program. Including universal primer
binding sites, the synthetic oligonucleotides product size was
within a range of 100–136 bp. For the purpose of ligation all right
probe oligos (RPOs) were 59 phosphorylated (Thermo Fisher
Scientific, Waltham, USA). 250 ng of genomic DNA were used to
carry out the MLPA reaction. The PCR products were separated
according to their length by capillary electrophoresis on an ABI
PRISM 3100 Genetic Analyzer. The corresponding copy number
of each locus was calculated by comparing the relative peak area of
every patient to the mean peak area of at least 5 control individuals
(probe ratios) in the MLPA module of the Sequence Pilot software
(JSI medical systems GmbH, Kippenheim, Germany). Probe ratios
under 75% indicated a deletion, whereas ratios over 125%
confirmed duplications.
Furthermore, segregation of copy number changes in the
families was confirmed by MLPA testing of the parental DNAs.
CNVs inherited from unaffected parents were excluded from
further investigation.
Association analysis
For the genome-wide copy number association analysis,
pseudomarkers were defined at the endpoints of each CNV
segment and the copy number status at this marker determined for
each individual. Gains and Losses were separately evaluated in a
permuted x2 based test with 100,000 status permutations
performed for each marker. Association analysis was performed
with PLINK v. 1.07 [37] and visualized with GPGraphics [38].
Expression arrays
The PAXgene Blood RNA Kit by Qiagen was used to extract
RNA from peripheral blood samples of the affected individuals.
Available RNAs of 14 of the 20 affected individuals with proposed
pathogenic CNVs were controlled for quantity and quality with an
Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA). When
quality standards were not passed, an additional purification was
carried out using the ‘‘RNeasy Mini Kit’’ according to the
manufacturer’s instructions (Qiagen, Hilden, Germany). RNA of 3
individuals did not achieve the necessary quality requirements and
were excluded from further analysis. Gene expression arrays of the
remaining 11 affected individuals and 5 healthy controls were
performed using the Affymetrix GeneChip Human Genome U133
Plus 2.0 Array. Expression data was analyzed with the PARTEK
software (Partek Incorporated, St. Louis, USA). After GCRMA
normalization, a one-way ANOVA analysis was performed to test
for significant differences in gene expression levels.
Pathway analysis
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems Inc.,
Redwood City, USA) was used to analyze potential functional
relationships between affected genes of all 20 identified CNVs. A
list of all affected genes (278 unique) as well as lists of all (60
unique), only deleted (21 unique), and only duplicated genes (39
unique) showing significant (p,0.05) differential expression of the
11 patients with expression array data available were analyzed.
The fold change minimum was set to 1.25 (up regulation) and
21.33 (down regulation), respectively. After uploading the
individual lists the software clustered genes according to their
connectivity into molecular networks, common biological func-
tions and canonical pathways. P-values and numerical scores were
calculated to rank networks according to their degree of relevance
in regards to the different gene lists. The calculated score is based
Figure 5. Genome-wide significant association of GWAS loci for height distribution in the 3 CNVs. The values of r2 are based on the CEU
1000genomes Nov 2010 samples. The blue line and right-hand y axis represent recombination rates. The SNPs with the min p values are highlighted
as purple diamond. The figures were created using LocusZoom (http://csg.sph.umich.edu/locuszoom/).
doi:10.1371/journal.pgen.1003365.g005
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on the hypergeometric distribution with the right-tailed Fisher’s
Exact Test. The score presents the negative log of the p-value.
GWAS comparison
We compared the position and gene content with the published
genome wide association data of the GAINT consortium (CEU
1000genomes Nov 2010 sample imputation) using LocusZoom
[32,33]. Under the estimation of approx. 2000 copy number
polymorphism of 50 kb or above in the human genome per
individual we calculated a genome wide level of significance of
2.561025.
Supporting Information
Figure S1 Copy number association of 200 patients and 820
control individuals. One-sided test of association of deviant copy
number state at a given location and disease status, both for
deletions (left) and duplications (right) after calculating the negative
decadic logarithms of corrected (Bonferroni for 17,168 tests)
permutation-based x2 p-values (10,000,000 permutations). The
horizontal line represents the estimated significance threshold of
genome wide CNV association (p-value 2.561025). One signifi-
cant deletion locus on chromosome 1 did not harbor genes or
regulatory elements with supportive evidence for an effect on
height.
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Figure S2 Graphical presentation of the copy number state and
MLPA confirmation. (A-T, upper pane) Presentation of the
calculated copy number for the patient (green), the mother
(magenta) and the father (blue) where available (Affymetrix
Genotyping console). (A-T, lower pane) MLPA confirmation of
one gene in each of the affected CNV regions vs. controls (C1-12).
MLPAs were carried out using the SALSA MLPA Reagents kit
and the P200 SALSA MLPA Reference kit according to the
manufacturer’s instructions (MRC Holland, Amsterdam, Nether-
lands). At least one MLPA probe per CNV was designed. The
corresponding copy number of each locus was calculated by
comparing the relative peak area of every patient to the mean peak
area of the control individuals (probe ratios) with the Sequence
Pilot software (JSI medical systems GmbH, Kippenheim, Ger-
many).
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Figure S3 GWAS loci in the identified 20 potential causal
CNVs. (A–T) The r2 values in the figure refer to the LD between
the GIANT SNPs based on the CEU 1000genomes Nov 2010
samples. The blue line and right-hand y axis represent
recombination rates. The SNP with the best p-value representing
the best r2 value is highlighted as purple diamond. The figures
were created using LocusZoom (http://csg.sph.umich.edu/
locuszoom/).
(DOCX)
Figure S4 Principal component analysis of 200 patients (red and
green) and 820 control individuals (blue). In the lower panel, the
area containing most individuals in the upper panel has been
expanded. In both groups, some samples scatter along the first
principal component, owing to a residual amount of ethnic
heterogeneity in both populations. Green data points indicate the
patients with potentially disease-causing copy number variants.
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Table S1 MLPA probes.
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Table S2 Murine knock-out phenotypes of the Mouse Genome
Informatics database (MGI) and Haploinsufficiency scores of genes
within the identified CNVs.
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Table S3 Candidate genes based on their function.
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Table S4 Detailed clinical data of patients with the identified 20
CNVs.
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Table S5 Association results for the identified CNVs from
genome wide association of human height variation GIANT
consortium data. Signals with p values,1.37761026 are marked
(*).
(DOCX)
Table S6 Significant differentially expressed candidate genes
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